PCI-34051

For research use only. Not for use in humans.

目录号：S2012

CAS No. 950762-95-5

PCI-34051是一种有效的，特异性的HDAC8抑制剂，无细胞试验中IC50为10 nM。比作用于HDAC1和6选择性高200多倍，比作用于HDAC2， 3，和10选择性高1000倍。PCI-34051可诱导半胱天冬酶依赖的凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1815.22	现货
10mg	RMB 1377.26	现货
100mg	RMB 9582.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PCI-34051发表文献37篇：

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Tuberculosis (Edinb), 2021, 127:102062

PubMed: 33639591 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5783

PubMed: 33188197 ( click the link to review the publication )

Theranostics, 2020, 10(15):6790-6805

PubMed: 32550904 ( click the link to review the publication )

Cell Death Dis, 2020, 11(12):1036

PubMed: 33279948 ( click the link to review the publication )

FASEB J, 2020, 12

PubMed: 32281211 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12):E4539

PubMed: 32630606 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

EXCLI J, 2020, 19:734-744

PubMed: 32636726 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2608-2621.e6

PubMed: 30840885 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007685

PubMed: 30779731 ( click the link to review the publication )

Biol Chem, 2019, 400(6):733-743

PubMed: 30521473 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Clin Hypertens, 2019, 25:13

PubMed: 31223486 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

J Med Chem, 2018, 61(22):10000-10016

PubMed: 30347148 ( click the link to review the publication )

Stem Cells Transl Med, 2018, 10.1002/sctm.18-0057

PubMed: 30426726 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )
Virol Sin, 2018, 33(5):418-428

PubMed: 30328580 ( click the link to review the publication )

Exp Mol Med, 2017, 49(2):e297

PubMed: 28232663 ( click the link to review the publication )

Chemistry, 2017, 23(13):3107-3116

PubMed: 27922200 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

J Cell Mol Med, 2016, 20(12):2289-2298

PubMed: 27420561 ( click the link to review the publication )

Horm Cancer, 2016, 7(3):196-210

PubMed: 26957440 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

J Immunol, 2015, 195(11):5421-31

PubMed: 26519528 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

BMC Biol, 2014, 12:95

PubMed: 25406762 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC8 ^[1]
(Cell-free assay)

10 nM

体外研究

PCI-34051有效作用于HDAC8，K_i为10 nM。与其他I型HDACs包括HDAC1相比，PCI-34051更高选择性作用于HDAC8。比作用于HDAC1和HDAC6选择性高200倍，比作用于 HDAC2, HDAC3 和HDAC10选择性高1000倍。PCI-34051抑制卵巢瘤细胞系OVCAR-3，GI50为6 μM，细胞死亡率为15%。PCI-34051浓度低于25 μM 时，处理敏感细胞系，在24小时而非更早时间点，观察不到显著的微管蛋白，也观察不到组蛋白乙酰化。PCI-34051 作用于T细胞恶性肿瘤衍生的细胞系，诱导选择性的细胞毒性作用。PCI-34051 诱导caspase依赖性凋亡。使用5 μM PCI-34051处理后，在不同时间点测量caspase-3活性, 在12 到24 到48 小时观察到活性水平提高，凋亡的另一种标志, 与更高水平caspase 活性一致。PCI-34051不刺激 Bid 分裂, Bid 分裂是外在凋亡通路的特性影响。P116 和 J.RT3-T.5 对PCI-34051敏感，PLCγ1缺陷的J.gamma1系显著降低 PCI-34051诱导凋亡的程度。此外, 稳定的钙水平也强烈影响PCI-34051诱导的凋亡。PCI-34051诱导细胞色素 c从线粒体中释放。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
LAN1	NWTJcYw3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MonPO\|IhcHK\|	NGq2eo5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBNSU5zIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhT0l3ME2zMlnPxE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFzNkG0O{c,OjNzMU[xOFc9N2F-
Jurkat	NXrCPGQ1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NITQd2c4OiCqcoO=	MVXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDKeZJs[XRiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUGx{txO	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFzNkG0O{c,OjNzMU[xOFc9N2F-
NB-1	MoTTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYPRWZhZPzJiaILz	MnPqS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmIuOSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTB;MUVOwG0>	NVqyOGNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNVYyPDdpPkKzNVE3OTR5PD;hQi=>
MT2	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4rzWVczKGi{cx?=	MlvUS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXQzKGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OD1zNd88US=>	NI\O[4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GxOlE1Pyd-MkOxNVYyPDd:L3G+
MT4	Mof4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHm1SHg4OiCqcoO=	M3vkUGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1VPCClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTB;MkZOwG0>	M1vNfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVQ4Lz5{M{GxOlE1PzxxYU6=
Huh7	Mn;RRY51cX[rcnHsJIF{e2G7		M{\DSlMh\GG7cx?=	MkjXRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGNXKGenbn;0fZBmKDGkIHnu[oVkfGWmIHnuJIh2dWGwIFj1bFch[2WubIOgZYZ1\XJiMzDkZZl{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2xMljPxE1?	MoizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUC3NFAoRjJ3NEmwO\|AxRC:jPh?=
HuH7	NEjtWnJEgXSxdH;4bYNqfHliYYPzZZk>		MkXaN{Bl[Xm\|	MkHhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJVJPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDNiZHH5d{BjgSCFZXzsWIl1\XJiOU[gZZN{[XluIFPDOVA:OTIQvF2=	NVvsPIdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVA4ODBpPkK1OFkxPzByPD;hQi=>
Sf9	NUHQS49TTnWwY4Tpc44h[XO\|YYm=		M33CNFUhdWmwcx?=	NVT3WWZxUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuLXzlcod1cCCqdX3hckBENXSncn3pcoFtKE[OQVetTIl{NXSjZ3fl[EBJTEGFMTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyC3c3nu[{BDd2NvTD3MfZMpSWNrLVHNR{BieyC\|dXLzeJJifGVicILlbY5kfWKjdHXkJIZweiB3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDN3IH3pcpMh[nliZnz1c5Jme2OnLDDJR\|UxRTNwON88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUe5Okc,Ojh6M{W3PVY9N2F-
Sf9	MV\GeY5kfGmxbjDhd5NigQ>?		NHK0Umc2KG2rboO=	MUTJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHytcIVv\3SqIFOteIVzdWmwYXygTIl{NXSjZ3fl[EBJTEGFMzCoN\|k2KHSxIES4PUBz\XOrZIXld{kwcHWvYX6gUmNQWjJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegRo9kNUxvTInzLGFkMS2DTVOgZZMhe3Wkc4TyZZRmKHC{ZYTy[YF1\WRiZn;yJFUhdWmwczDmc4xtd3enZDDifUB{fWK\|dILheIUh[WSmaYTpc44hdWWjc4Xy[YQtKEmFNUC9O{4y\|ryP	M4LXdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEO1O\|k3Lz5{OEizOVc6PjxxYU6=
Sf9	MUDGeY5kfGmxbjDhd5NigQ>?		NHjaSIM2KG2rboO=	MorUTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDDMZRmem2rbnHsJGhqey22YXfn[YQhUESDQ{Kg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmPUBqdnOnY4SgZ4VtdHNidYPpcochSm:lLVytUJl{MEGlKT3BUWMh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EBnd3JiNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB\|NTDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1\|Md88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUe5Okc,Ojh6M{W3PVY9N2F-
SH-SY5Y	M1fyOmN6fG:2b4jpZ4l1gSCjc4PhfS=>			MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiVGC1N{BjgSCFZXzsWIl1\XJ7NjDBVZVmd3W\|IH;u[UB{d2y3dHnvckBk\WyuIIDyc4xq\mW{YYTpc44h[XO\|YYm=	MnLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{W3PVYoRjJ6OEO1O\|k3RC:jPh?=
IMR5	MmO1R5l1d3SxeHnjbZR6KGG\|c3H5			M2TaRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlOWjViY3XscJMh\XiycnXzd4lv\yCWUEWzJIJ6KEOnbHzUbZRmejl4IFHReYVwfXNib37lJJNwdHW2aX;uJINmdGxicILvcIln\XKjdHnvckBie3OjeR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUe5Okc,Ojh6M{W3PVY9N2F-
SK-N-AS	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=			MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1PNUGVIHPlcIx{KGW6cILld5NqdmdiVGC1N{BufXSjdHnvckBjgSCFZXzsWIl1\XJ7NjDBVZVmd3W\|IH;u[UB{d2y3dHnvckBk\WyuIIDyc4xq\mW{YYTpc44h[XO\|YYm=	NHPRSnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pid-Mki4N\|U4QTZ:L3G+
Kelly	MnOxR5l1d3SxeHnjbZR6KGG\|c3H5			NFXFRpZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIGTQOVMhdXW2YYTpc44h[nliQ3XscHRqfGW{OU[gRXF2\W:3czDvcoUhe2:udYTpc44h[2WubDDwdo9tcW[ncnH0bY9vKGG\|c3H5	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUe5Okc,Ojh6M{W3PVY9N2F-
BE(2)-C	NEnIRlFEgXSxdH;4bYNqfHliYYPzZZk>		Ml;4O\|IhcHK\|	Mn;lR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmUpOilvQzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZpkhdWWjc4XybY5oKG2ndHHic4xq[yCjY4Tpeol1gSCjZoTldkA4OiCqcoOgZpkhX1OWLUigZZN{[XluIFnDOVA:OTlwOd88US=>	Ml7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
Sf9	MkTlSpVv[3Srb36gZZN{[Xl?		MUW5NEBucW6\|	M2qzRWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBHVEGJLYTh[4dm\CCKRFHDNUBmgHC{ZYPz[YQhcW5iZnHscEBiem27d3;ycUBU\jliY3XscJMhfXOrbneg[ox2d3KxZ3XubYMhYk2DTDDhd{B{fWK\|dILheIUh[W[2ZYKgPVAhdWmwczDifUBndHWxcnnt[ZRzcWNiYX7hcJl{cXNuIFnDOVA:OjhwM988US=>	MkjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
Sf9	M2PXemZ2dmO2aX;uJIF{e2G7		MWO5NEBucW6\|	MYnJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFjERWM3KGW6cILld5Nm\CCrbjDmZYxtKGG{bYn3c5JuKFOoOTDj[YxteyC3c3nu[{BndHWxcn;n[Y5q[yCcTVHMJIF{KHO3YoP0doF1\SCjZoTldkA6OCCvaX7zJIJ6KG[udX;ybY1mfHKrYzDhcoFtgXOrczygTWM2OD12OD6y{txO	Mn\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
BE(2)-C	NX3wUoF4TnWwY4Tpc44h[XO\|YYm=	NG[zUXQ3KHWP	MYC3NkBpenN?	M4\qcWlvcGmkaYTpc44hd2ZiSFTBR\|ghcW5iaIXtZY4hSkVqMjmtR{Bk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gdFIyN0OGS16xJIdmdmViZYjwdoV{e2mxbjDheEA3KHWPIHHmeIVzKDd{IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMhemWuYYTpeoUhfG9iY3;ueJJwdA>?	NIf4ZWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG5NFA6Oid-MkmxPVAxQTJ:L3G+
BE(2)-C	NVW1SmJETnWwY4Tpc44h[XO\|YYm=	NV:4fXQzPiC3TR?=	NV7kOlFkPzJiaILz	MWDJcohq[mm2aX;uJI9nKEiGQVO4JIlvKGi3bXHuJGJGMDJrLVOgZ4VtdHNiYYPz[ZN{\WRiYYOgeZBz\We3bHH0bY9vKG:oIGTyb2EwVlSUS{Gg[4Vv\SCneIDy[ZN{cW:wIHH0JFYhfU1iYX\0[ZIhPzJiaILzJIJ6KFKWLWDDVkBidmGueYPpd{Bz\WyjdHn2[UB1dyClb370do9t	NWrWfnRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxPVAxQTJpPkK5NVkxODl{PD;hQi=>
BE(2)-C	MVfGeY5kfGmxbjDhd5NigQ>?	NYfTXVd4PiC3TR?=	NFPVWlI4OiCqcoO=	NGTsfWVKdmirYnn0bY9vKG:oIFjERWM5KGmwIHj1cYFvKEKHKEKpMWMh[2WubIOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJHRJKGenbnWg[ZhxemW\|c3nvckBifCB4IIXNJIFnfGW{IEeyJIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MlPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
BE(2)-C	NVSxfXV3TnWwY4Tpc44h[XO\|YYm=	MVS2JJVO	NXvTNXhnPiCmYYnz	M{\WVGlv\HWldHnvckBw\iCxdYTndo94fGhib3[gcoV2em:oaXzhcYVvfCCyb4PpeIl3\SCwZYX0dol1\S2uaXvlJJN1enWldIXy[ZMhcW5iaIXtZY4hSkVqMjmtR{Bk\WyuczDheEA3KHWPIHHmeIVzKDZiZHH5d{BjgSCGQWDJMZN1[WmwaX7nJIJie2WmIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz	MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
A673	NGPkPIJyUFSVIHHzd4F6			MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MnrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MYTxTHRUKGG\|c3H5			MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NWjJXY5weUiWUzDhd5NigQ>?			NVLuWZB[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NVXmc4VKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	M2XoepFJXFNiYYPzZZk>			M3n2PZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NHrIb2xyUFSVIHHzd4F6			NFjxbY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	NIfHW3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MorMdWhVWyCjc4PhfS=>			MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MnHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Jurkat	NHG5V4FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NHrqOXdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiR1m1NF0zNjUQvF2=	Mm\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MEW5N\|UoRjJ7NUC1PVM2RC:jPh?=
HUT78	NVnCSI5sSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M1q1RmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXUO\|gh[2WubIOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEeLNUC9Nk41\|ryP	M3\GS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUC1PVM2Lz5{OUWwOVk{PTxxYU6=
HSB2	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NITWcYJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjTRlIh[2WubIOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEeLNUC9Nk41\|ryP	NXPXeI5CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NFU6OzVpPkK5OVA2QTN3PD;hQi=>
MOLT4	NFzPfVVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MoPZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zUOEBk\WyuczDifUBidGGvYYKgZox2\SCjc4PhfUwhT0l3ME2yMlTPxE1?	M{WwSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUC1PVM2Lz5{OUWwOVk{PTxxYU6=
Jurkat	NVvsR2tVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M16zSFQ5KGi{cx?=	M3HHZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;ND61{txO	NEXqXJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzN\|g4Oyd-Mkm1N\|M5PzN:L3G+
MOLT4	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlfxOFghcHK\|	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:QS52zszN	M1zOOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUOzPFc{Lz5{OUWzN\|g4OzxxYU6=
HEL	MmfvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXW0PEBpenN?	NEPhTY9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjFUEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTFyLklOwG0>	NWjpNYFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
SK-N-BE(2)	NXL1XVd2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmjGOFghcHK\|	NELwS\|lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uSkVqMjmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yPi57zszN	NYfQR5pjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
PC3	M3HwZ2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2m3ZlQ5KGi{cx?=	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE6NjMQvF2=	NWDxRndqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
K562	MlnhRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2f6TFczKGi{cx?=	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NF0zNjBzzszN	NF;LNGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOFY6Pyd-M{CwNFQ3QTd:L3G+
K562R	M3\MfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2PDfFczKGi{cx?=	M361eGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NnIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OD1{LkNOwG0>	MofXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByMES2PVcoRjNyMEC0Olk4RC:jPh?=
HCT116	MoHZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVG3NkBpenN?	NGjXTmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUKuOlTPxE1?	NYr5RZhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFQ3QTdpPkOwNFA1Pjl5PD;hQi=>
PC3	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEWzSoE4OiCqcoO=	MmLURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NF0zNjZ4zszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNE[5O{c,OzByMES2PVc9N2F-
MCF7	NVXCXVVkSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mk\XO\|IhcHK\|	MlzrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVA:Oi57N988US=>	M2HvNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC0Olk4Lz5\|MECwOFY6PzxxYU6=
BL21 (DE3)	NEjUepBHfW6ldHnvckBie3OjeR?=			M4jzZmJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gTIl{NXSqaX;y[YRwgGmwLYTh[4dm\CCKRFHDPEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KGK7IFnUR{Bu\XSqb3SsJGtlRTBwMEe1Ne69VQ>?	MoP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NEexOFgoRjNyM{S3NVQ5RC:jPh?=
BL21 (DE3)	MWHGeY5kfGmxbjDhd5NigQ>?			NHvrenpKdmirYnn0bY9vKG:oIHj1cYFvKEircz30bIlwemWmb4jpck11[WepZXSgTGRCSzhiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczD1d4lv\yCIbIXvdkBl\SCOeYOgLHIqNUiGQVO4JIF{KHO3YoP0doF1\SCkeTDmcJVwem:vZYTybYMhdWW2aH;kMEBKSzVyPUCuNFc4P87:TR?=	NH2yWnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3)	NGXnT3BHfW6ldHnvckBie3OjeR?=			NF;6W2FDcW6maX7nJIFn\mmwaYT5JJRwKFOlaHnzeI9{d22jIH3hcpNwdmliSHnzMZRi\2enZDDISGFEQCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy\|IHL5JGlVSyCvZYToc4QtKEumPUCuN\|Y4\|ryP	NXLob441RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFcyPDhpPkOwN\|Q4OTR6PD;hQi=>
BL21 (DE3)	NVLsOlZnTnWwY4Tpc44h[XO\|YYm=			M1nJVWlvcGmkaYTpc44hd2ZiU3PobZN1d3OxbXGgcYFve2:waTDIbZMufGGpZ3XkJGhFSUN6IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgeZNqdmdiRnz1c5Ih\GViTInzJEhTMS2KRFHDPEBieyC\|dXLzeJJifGViYomg[ox2d3KxbXX0dolkKG2ndHjv[EwhUUN3ME2wMlQ{PTkQvF2=	M331NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5\|MEO0O\|E1QDxxYU6=
BL21 (DE3)	NGKwPYJHfW6ldHnvckBie3OjeR?=			M3[0emlvcGmkaYTpc44hd2ZiaIXtZY4hUGm\|LYTobY9z\WSxeHnuMZRi\2enZDDISGFEQCCvTE[vUFE4QUlibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNidYPpcochTmy3b4Kg[IUhVHm\|IDjSLU1JTEGFODDhd{B{fWK\|dILheIUh[nliZnz1c5JwdWW2cnnjJI1mfGixZDygTWM2OD1zzszN	MmHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NEexOFgoRjNyM{S3NVQ5RC:jPh?=
BL21 (DE3)	M2LxVmZ2dmO2aX;uJIF{e2G7			NFnWV2dKdmirYnn0bY9vKG:oIHj1cYFvKEircz30bIlwemWmb4jpck11[WepZXSgTGRCSzhibVy2JI12fGGwdDDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzIDjESVMqKGOnbHzzJJV{cW6pIF\seY9zKGSnIFz5d{ApWilvSFTBR\|gh[XNic4Xid5Rz[XSnIHL5JIZtfW:{b33leJJq[yCvZYToc4QtKEmFNUC9NU43O87:TR?=	NGK1[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3)	MXnGeY5kfGmxbjDhd5NigQ>?			M2X3SGlvcGmkaYTpc44hd2ZiaIXtZY4hUGm\|LYTobY9z\WSxeHnuMZRi\2enZDDISGFEQCCvTEGvcWw3KG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KHW\|aX7nJGZtfW:{IHTlJGx6eyBqUjmtTGRCSzhiYYOgd5Vje3S{YYTlJIJ6KG[udX;yc41mfHKrYzDt[ZRpd2RuIFnDOVA:Oi55zszN	M2LBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5\|MEO0O\|E1QDxxYU6=
BL21 (DE3)	MkHKSpVv[3Srb36gZZN{[Xl?			MUDJcohq[mm2aX;uJI9nKGi3bXHuJGhqey22aHnvdoVld3irbj30ZYdo\WRiSFTBR\|ghdUxzL33MOk9NOTd7STDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczD1d4lv\yCIbIXvdkBl\SCOeYOgLHIqNUiGQVO4JIF{KHO3YoP0doF1\SCkeTDmcJVwem:vZYTybYMhdWW2aH;kMEBKSzVyPUZOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
Sf9	M1H2OGZ2dmO2aX;uJIF{e2G7			MnrNTY5pcWKrdHnvckBw\iCFLYTldo1qdmGuIF\MRWcwUGm\|LYTh[4dm\CCodXzsJIxmdme2aDDoeY1idiCKRFHDNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4Y6KGmwc3XjeEBk\WyuczD1d4lv\yCcKFHjLWx6ey2DTVOgZZMhe3Wkc4TyZZRmKGK7IH\seY9zd22ndILpZ{Bu\XSqb3SsJGlEPTB;MkiuN:69VQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
Sf9	M{PpSWZ2dmO2aX;uJIF{e2G7			MnjUTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE11[WepZXSg[pVtdCCuZX7neIghcHWvYX6gTGRCSzZiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegXkhC[ymOeYOtRW1EKGG\|IIP1ZpN1emG2ZTDifUBndHWxcn;t[ZRzcWNibXX0bI9lNCCLQ{WwQVQ5NjMQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
Sf9	NUfufpdQTnWwY4Tpc44h[XO\|YYm=		MX60NEBucW6\|	M2fVTmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXNvdHHn[4VlKEiGQVO4JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgOFAhdWmwczDifUBJTEGFLVfsc\|EwOiCudX3pcoV{[2WwdDDhd5NigSxiSVO1NF0xNjB\|MU[y{txO	M1LvelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOU[0NlkxLz5\|MEm2OFI6ODxxYU6=
SK-N-BE(2)C	NXTMR5pOSW62aXPsc45w\2WwaXOgZZN{[Xl?		NXPCRmk1QTZiaILz	MYrBcpRq[2yxbn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCVSz3OMWJGMDJrQzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDwdo9tcW[ncnH0bY9vKGmwY4XiZZRm\CCob4KgPVYhcHK\|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pIHLhd4VlKGG\|c3H5MEBIUTVyPUG1{txO	NUTNbI1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G2N\|AxPTRpPkOxOlMxODV2PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Immunofluorescence	SMC3 / Ac-SMC3 ; PubMed: 27072133 J Biol Chem A and B, representative immunofluorescence analysis of total- and ac-SMC3 in G1-S synchronized MCF7 cells treated with the indicated concentrations of PCI-34051 for 6 and 12 h, respectively. MCF7 cells grown in complete medium were synchronized to G1-S phase by double thymidine block and released in the presence of different concentrations of PCI-34051 for 6 or 12 h. Cells were stained for DNA (Hoechst-H33342, blue) and with antibodies detecting total-SMC3 (green) and ac-SMC3 (red). Cells were analyzed by Nikon C2 confocal microscope; images were taken at 20× magnification (z-series) using the NIS elements software, z-stacked, and processed using FIJI.	27072133

激酶实验：^[1]	- 合并组蛋白去乙酰化酶活性: 使用96孔实验板上，反应体积为100 μL，在荧光酶标仪上测量PCI-34051特性。HDAC 蛋白在反应buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 5% DMSO, pH7.4,伴有牛血清蛋白，浓度为0-0.05%)中与不同浓度PCI-34051混合，再温育15分钟，测定每种酶。加入胰蛋白酶，终浓度为50 nM,加入乙酰基-gly-Ala-(N-乙酰基-Lys)-氨基-4-甲基香豆素，终浓度为25-100 μM，开始反应。停滞30分钟后, 使用激发波长为335 nm，检测波长为460 nm，在30分钟时间范围测量荧光值。测量的荧光值的增量用了衡量反应速率。
细胞实验：^[1]	- 合并 Cell lines: A549 细胞系, Ovcar-3 细胞系 Concentrations: 5 μM Incubation Time: 24 小时 Method: 肿瘤细胞系和人脐静脉内皮细胞培养至少两次倍增时间，PCI-34051处理末期，通过Alamar Blue荧光细胞增殖检测实验监测生长。PCI-34051重复三份加入96孔板中。使用四参数方程，通过非线性回归估量抑制 50% 细胞生长所需浓度(GI50)和95%置信区间。 (Only for Reference)

参考文献

[1] Balasubramanian S, et al. Leukemia. 2008, 22(5), 1026-1034.

溶解度 (25°C)

体外	DMSO	59 mg/mL (199.1 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40%PEG300+5% tween80+50% H2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PCI-34051 SDF

分子量	296.32
化学式	C₁₇H₁₆N₂O₃
CAS号	950762-95-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

泛HDAC抑制剂

Panobinostat (LBH589) : Pan-HDAC inhibitor, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

定制您的化合物库

PCI-34051

客户使用Selleck生产的PCI-34051发表文献37篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PCI-34051 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品